Holders of warrants of series 2019/2021 subscribed for 42,787,137 warrants, corresponding to 99.41 percent of the outstanding warrants, for subscription of 42,787,137 shares of series B at the subscribtion price of SEK 0.65. Through the exercise of the warrants, ADDvise receives SEK 27,811,639 before issue costs.
During the first quarter of 2019, ADDvise carried out a rights issue of units, consisting of one (1) newly issued series B share and one (1) warrant of series 2019/2021. Each warrant of series 2019/2021 entitled the holder to subscribe for one (1) new B share in ADDvise. The subcription period ran January 25, 2021 and February 8, 2021.
Exercised warrants have been replaced with interim shares (IA) pending registration at Bolagsverket. The conversion of interim shares into shares of series B is expected to take place within approximately three weeks.
Complete terms and conditions for the warrants are available on the Company's website, www.addvisegroup.se.
Number of shares and share capital
Through the exercise of the warrants, the number of shares in ADDvise increases by 42,787,137 shares, from 96,913,631 to 139,700,768 shares. The share capital increases by SEK 4,278,713,7 from SEK 9,691,363.1 to SEK 13,970,076,8.
For existing shareholders who have not exercised any warrants of series 2019/2021, the dilution amounts to approximately 31.08 percent.
Mangold Fondkommission is financial adviser and Advokatfirman Schjødt is legal advisor to ADDvise in connection with the exercise of warrants of series 2019/2021.
For questions regarding the warrants, please contact:
Mangold Fondkommission AB
Tel: +46 8 5030 1595
For further information:
Hanna Myhrman, General Counsel
Tel: +46 709 82 92 23
This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on 10 February 2021 at 08:00 CET.
ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business - both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50,